Note 11 - Segment Reporting (Tables)

9 Months Ended

Sep. 30, 2025

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Three Months Ended September 30,						Nine Months Ended September 30,
	2025			2024			2025			2024
Revenue	$	72,413		$	4,933		$	133,019		$	13,515
Less:
Research and development
External program costs:
Norovirus program		519			821			3,227			2,560
COVID-19 program		66,220			1,513			118,413			7,849
Other programs		-			2			346			16
Preclinical research		98			216			722			1,596
Process Development		—			106			46			189
Internal research and development costs		9,110			12,408			33,672			39,349
General and administrative		4,277			4,342			13,942			16,757
Interest income		(302	)		(1,022	)		(1,049	)		(1,941	)
Non-cash interest expense related to sale of future royalties		608			631			2,277			2,045
Other segment items(A)		7			(22	)		9			(26	)
Provision for income taxes		17			18			132			84
Segment net loss	$	(8,141	)	$	(14,080	)	$	(38,718	)	$	(54,963	)
Reconciliation of net loss
Adjustments and reconciling items		—			—			—			—
Net loss	$	(8,141	)	$	(14,080	)	$	(38,718	)	$	(54,963	)